A Phase 2 interventional study of GLPG0634 and Placebo in Rheumatoid Arthritis, sponsored by Galapagos NV. Completed at 82 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-16.
Sponsored by Galapagos NV · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing GLPG0634 in Arthritis, Rheumatoid — 4 open to participants now, 4 under way, none of them phase 3. GLPG0634 · Arthritis, Rheumatoid.
Among the 17 studies testing GLPG0634 in Arthritis, Rheumatoid, this one is the 9th largest by enrollment, is one of 2 that started in 2013, is one of 6 in phase 2, and was the 4th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 17 studies testing GLPG0634 in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
University Hospital, Toulouse · Sites in France
Ages 18–65
Universita di Verona · Sites in Italy
Ages 18–65
R.Bos · Sites in Netherlands
Ages 18–101
Leiden University Medical Center · Sites in Netherlands
Ages 18+
By country, each count listing its studies:
GLPG0634: first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 287 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 287 across the 17 interventional studies. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 8 most frequent:
This study is registered under Galapagos NV, one of the names counted as Lakefront Biotherapeutics NV. Under that name alone:
Galapagos NV is the lead sponsor of 103 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 11 (79%) have results posted.
Lakefront Biotherapeutics NV has 8 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing GLPG0634 in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
have ≥6 swollen joints (from a 66-joint count) and
≥8 tender joints (from a 68-joint count) at Screening and at Baseline,
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received GLPG0634 matching placebo capsules, orally, once daily (QD) during Weeks 1 to 12 and GLPG0634 100 milligram (mg) QD during Weeks 13 to 24.
Drug: Placebo
Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.
Drug: GLPG0634
Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.
Drug: GLPG0634
Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.
Drug: GLPG0634
GLPG0634 capsules.
Placebo capsules.
Percentage of Participants Achieving an American College of Rheumatology (ACR) 20 Response at Week 12
The American College of Rheumatology (ACR) response is a measurement of improvement in multiple disease assessment criteria. The ACR20 response is defined as: 1) ≥ 20% improvement from baseline in SJC66, and 2) ≥ 20% improvement from baseline in tender TJC68, and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain visual analog scale (VAS) (taken from the Health Assessment Questionnaire - Disability Index \[HAQ-DI\]), 2. Patient's Global Assessment of Disease Activity VAS, 3. Physician's Global Assessment of Disease Activity VAS, 4. Total HAQ-DI score, and 5. CRP. Non-responder imputation was used (ie, to impute a missing response, the participant was assumed to be a non-responder).
Time frame: Week 12
Percentage of Participants Achieving an ACR20 Response at Week 24
ACR20 response was defined as: 1) ≥ 20% improvement from baseline in SJC66, and 2) ≥ 20% improvement from baseline in TJC68, and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2. Patient's Global Assessment of Disease Activity VAS, 3. Physician's Global Assessment of Disease Activity VAS, 4. Total HAQ-DI score, and 5. CRP. Non-responder imputation was used.
Time frame: Week 24
Percentage of Participants Achieving an ACR50 Response at Weeks 1, 2, 4, 8, 12, and 24
ACR50 response was defined as: 1) ≥ 50% improvement from baseline in SJC66, and 2) ≥ 50% improvement from baseline in TJC68, and 3) ≥ 50% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI) 2. Patient's Global Assessment of Disease Activity VAS 3. Physician's Global Assessment of Disease Activity VAS 4. Total HAQ-DI score 5. CRP. Non-responder imputation was used. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.
Time frame: Weeks 1, 2, 4, 8, 12, and 24
Percentage of Participants Achieving an ACR70 Response at Weeks 1, 2, 4, 8, 12, and 24
ACR70 response: 1) ≥ 70% improvement from baseline in SJC66, and 2) ≥ 70% improvement from baseline in TJC68, and 3) ≥ 70% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2. Patient's Global Assessment of Disease Activity VAS, 3. Physician's Global Assessment of Disease Activity VAS, 4. Total HAQ-DI score, and 5. CRP. Non-responder imputation was used. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.
Time frame: Weeks 1, 2, 4, 8, 12, and 24
ACR N% Improvement (ACR-N) Response at Weeks 1, 2, 4, 8, 12, and 24
The ACR-N is the smallest percentage improvement in swollen and tender joints and the median of the remaining 5 core parameters, and is expected to be more sensitive to change than the ACR20, ACR50 or ACR70. It is a number varying between 0 and 100, with higher numbers indicating less severity of symptoms. Last observation carried forward (LOCF) algorithm was used (ie, to impute a missing value, the last preceding nonmissing value was used). All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.
Time frame: Weeks 1, 2, 4, 8, 12, and 24
Percentage of Participants With Disease Activity Score 28 Joints Corrected for CRP (DAS28 (CRP)) European League Against Rheumatism (EULAR) Response at Weeks 1, 2, 4, 8, 12, and 24
DAS28 (CRP) was categorized into EULAR response categories (none, moderate, good) as follows: None = Actual DAS28 (CRP) ≤ 3.2, \> 3.2 to ≤ 5.1, or \> 5.1 AND Improvement in DAS28 (CRP) from baseline ≤ 6.0 or \> 0.6 to ≤ 1.2; Moderate = Actual DAS28 (CRP) ≤ 3.2 AND Improvement in DAS28 (CRP) from baseline \> 0.6 to ≤ 1.2, Actual DAS28 (CRP) \> 3.2 to ≤ 5.1 or \> 5.1 AND Improvement in DAS28 (CRP) from baseline \> 1.2, or Actual DAS28 (CRP) \> 3.2 to ≤ 5.1 AND Improvement in DAS28 (CRP) from baseline \> 0.6 to ≤ 1.2; Good = Actual DAS28 (CRP) ≤ 3.2 AND Improvement in DAS28 (CRP) from baseline \> 1.2. LOCF algorithm was used. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.
Time frame: Weeks 1, 2, 4, 8, 12, and 24
Percentage of Participants Achieving ACR/EULAR Remission at Weeks 2, 4, 8, 12, and 24
A participant's disease activity status can be defined as being in remission when scores on the TJC28, SJC28, CRP (actual value in mg/dL) and Patient Global Assessment of Disease Activity (cm) are all ≤ 1. Non-responder imputation was used. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.
Time frame: Weeks 4, 8, 12, and 24
Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 1, 2, 4, 8, 12, and 24
The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, Patient Global Assessment of Disease Activity (in cm), Physician's Global Assessment of Disease Activity (in cm), and CRP (mg/dL). The SDAI was categorized as follows: • High disease activity: SDAI \> 26 • Moderate disease activity: 11 to 26 • Low disease activity: 3.3 to 11 • Remission: ≤ 3.3. LOCF algorithm was used. The SDAI total score ranges from 0 to approximately 86. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.
Time frame: Baseline and Weeks 1, 2, 4, 8, 12, and 24
Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 1, 2, 4, 8, 12, and 24
The CDAI is the SDAI modified to exclude CRP and is the sum of the 4 outcome parameters: TJC28, SJC28, Patient Global Assessment of Disease Activity (in cm), and Physician's Global Assessment of Disease Activity (in cm). The CDAI was be categorized as follows: • High disease activity: \> 22 • Moderate disease activity: 10 to 22 • Mild disease activity: 2.8 to 10 • Remission: ≤ 2.8. LOCF algorithm was used. The CDAI total score ranges from 0 to approximately 76. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.
Time frame: Baseline and Weeks 1, 2, 4, 8, 12, and 24
Change From Baseline in Quality of Life Using the Functional Assessment of Chronic Illness Therapy (FACIT) at Weeks 4, 12, and 24
FACIT-Fatigue scale is a 13-item questionnaire, each scored on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated that are scored reversely), the greater the fatigue. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score), with a higher score indicating a better quality of life. LOCF algorithm was used. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.
Time frame: Baseline and Weeks 4, 12, and 24
Change From Baseline in Quality of Life Using the Short Form-36 (SF-36) Scores at Weeks 4, 12, and 24
The SF-36 is a 36-item questionnaire measuring 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health). Each domain score ranges from 0 (worst) to 100 (best), with higher scores reflecting better health-related functional status. Two summary scale scores were computed based on weighted combinations of the 8 domain scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). LOCF algorithm was used. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.
Time frame: Baseline and Weeks 4, 12, and 24
Participants were enrolled at study sites in Latin America, Europe, United States, and New Zealand. The first participant was screened on 08 October 2013. The last study visit occurred on 29 May 2015.
| Milestone | Placebo | GLPG0634 50 mg QD | GLPG0634 100 mg QD | GLPG0634 200 mg QD |
|---|---|---|---|---|
| Started | 72 | 72 | 70 | 69 |
| Completed | 65 | 67 | 67 | 66 |
| Not completed | 7 | 5 | 3 | 3 |
| Withdrew: Other | 0 | 1 | 1 | 0 |
| Withdrew: Adverse event and treatment failure | 2 | 0 | 0 | 0 |
| Withdrew: Non compliance with the study medication | 1 | 1 | 0 | 0 |
| Withdrew: Treatment failure | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 2 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 3 | 1 | 2 |
| Milestone | Placebo | GLPG0634 50 mg QD | GLPG0634 100 mg QD | GLPG0634 200 mg QD |
|---|---|---|---|---|
| Started | 0 | 52 | 147 | 66 |
| Completed | 0 | 50 | 142 | 65 |
| Not completed | 0 | 2 | 5 | 1 |
| Withdrew: Adverse event | 0 | 2 | 3 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 0 |
The American College of Rheumatology (ACR) response is a measurement of improvement in multiple disease assessment criteria. The ACR20 response is defined as: 1) ≥ 20% improvement from baseline in SJC66, and 2) ≥ 20% improvement from baseline in tender TJC68, and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain visual analog scale (VAS) (taken from the Health Assessment Questionnaire - Disability Index \[HAQ-DI\]), 2. Patient's Global Assessment of Disease Activity VAS, 3. Physician's Global Assessment of Disease Activity VAS, 4. Total HAQ-DI score, and 5. CRP. Non-responder imputation was used (ie, to impute a missing response, the participant was assumed to be a non-responder).
| percentage of participants | Placebo | GLPG0634 50 mg QD | GLPG0634 100 mg QD | GLPG0634 200 mg QD |
|---|---|---|---|---|
| Percentage of Participants Achieving an American College of Rheumatology (ACR) 20 Response at Week 12 | 29.2 | 66.7 | 65.7 | 72.5 |
ACR20 response was defined as: 1) ≥ 20% improvement from baseline in SJC66, and 2) ≥ 20% improvement from baseline in TJC68, and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2. Patient's Global Assessment of Disease Activity VAS, 3. Physician's Global Assessment of Disease Activity VAS, 4. Total HAQ-DI score, and 5. CRP. Non-responder imputation was used.
| percentage of participants | GLPG0634 50 mg QD | GLPG0634 100 mg QD | GLPG0634 200 mg QD |
|---|---|---|---|
| Percentage of Participants Achieving an ACR20 Response at Week 24 | 56.9 | 78.6 | 66.7 |
ACR50 response was defined as: 1) ≥ 50% improvement from baseline in SJC66, and 2) ≥ 50% improvement from baseline in TJC68, and 3) ≥ 50% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI) 2. Patient's Global Assessment of Disease Activity VAS 3. Physician's Global Assessment of Disease Activity VAS 4. Total HAQ-DI score 5. CRP. Non-responder imputation was used. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.
| percentage of participants | Placebo | GLPG0634 50 mg QD | GLPG0634 100 mg QD | GLPG0634 200 mg QD |
|---|---|---|---|---|
| Week 1 | 1.4 | 1.4 | 10 | 7.2 |
| Week 2 | 4.2 | 5.6 | 7.1 | 21.7 |
| Week 4 | 4.2 | 15.3 | 18.6 | 23.2 |
| Week 8 | 5.6 | 16.7 | 25.7 | 31.9 |
| Week 12 | 11.1 | 34.7 | 37.1 | 43.5 |
| Week 24 | — | 33.3 | 38.6 | 44.9 |
ACR70 response: 1) ≥ 70% improvement from baseline in SJC66, and 2) ≥ 70% improvement from baseline in TJC68, and 3) ≥ 70% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2. Patient's Global Assessment of Disease Activity VAS, 3. Physician's Global Assessment of Disease Activity VAS, 4. Total HAQ-DI score, and 5. CRP. Non-responder imputation was used. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.
| percentage of participants | Placebo | GLPG0634 50 mg QD | GLPG0634 100 mg QD | GLPG0634 200 mg QD |
|---|---|---|---|---|
| Week 1 | 0 | 0 | 1.4 | 1.4 |
| Week 2 | 2.8 | 1.4 | 1.4 | 4.3 |
| Week 4 | 1.4 | 8.3 | 5.7 | 11.6 |
| Week 8 | 2.8 | 6.9 | 11.4 | 17.4 |
| Week 12 | 2.8 | 8.3 | 18.6 | 13 |
| Week 24 | — | 19.4 | 25.7 | 24.6 |
The ACR-N is the smallest percentage improvement in swollen and tender joints and the median of the remaining 5 core parameters, and is expected to be more sensitive to change than the ACR20, ACR50 or ACR70. It is a number varying between 0 and 100, with higher numbers indicating less severity of symptoms. Last observation carried forward (LOCF) algorithm was used (ie, to impute a missing value, the last preceding nonmissing value was used). All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.
| percentage of improvement | Placebo | GLPG0634 50 mg QD | GLPG0634 100 mg QD | GLPG0634 200 mg QD |
|---|---|---|---|---|
| Week 1 | 6.79 ± 1.34 | 11.66 ± 1.641 | 12.84 ± 2.291 | 16.8 ± 2.346 |
| Week 2 | 10.79 ± 1.917 | 17.11 ± 2.362 | 16.06 ± 2.261 | 27.01 ± 2.776 |
| Week 4 | 12.03 ± 2.058 | 25 ± 2.852 | 24.06 ± 2.898 | 32.21 ± 3.172 |
| Week 8 | 13.35 ± 2.24 | 30.46 ± 2.986 | 32.66 ± 3.154 | 39.24 ± 3.375 |
| Week 12 | 16.28 ± 2.723 | 35.03 ± 3.178 | 38.35 ± 3.533 | 41 ± 3.477 |
| Week 24 | — | 38.75 ± 3.748 | 46.32 ± 3.295 | 46.78 ± 3.648 |
DAS28 (CRP) was categorized into EULAR response categories (none, moderate, good) as follows: None = Actual DAS28 (CRP) ≤ 3.2, \> 3.2 to ≤ 5.1, or \> 5.1 AND Improvement in DAS28 (CRP) from baseline ≤ 6.0 or \> 0.6 to ≤ 1.2; Moderate = Actual DAS28 (CRP) ≤ 3.2 AND Improvement in DAS28 (CRP) from baseline \> 0.6 to ≤ 1.2, Actual DAS28 (CRP) \> 3.2 to ≤ 5.1 or \> 5.1 AND Improvement in DAS28 (CRP) from baseline \> 1.2, or Actual DAS28 (CRP) \> 3.2 to ≤ 5.1 AND Improvement in DAS28 (CRP) from baseline \> 0.6 to ≤ 1.2; Good = Actual DAS28 (CRP) ≤ 3.2 AND Improvement in DAS28 (CRP) from baseline \> 1.2. LOCF algorithm was used. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.
| percentage of participants | Placebo | GLPG0634 50 mg QD | GLPG0634 100 mg QD | GLPG0634 200 mg QD |
|---|---|---|---|---|
| Week 1: None | 72 | 57 | 63 | 49 |
| Week 1: Moderate | 26 | 40 | 31 | 43 |
| Week 1: Good | 1 | 3 | 6 | 7 |
| Week 2: None | 67 | 44 | 47 | 26 |
| Week 2: Moderate | 31 | 49 | 46 | 64 |
| Week 2: Good | 3 | 7 | 7 | 10 |
| Week 4: None | 58 | 38 | 39 | 22 |
| Week 4: Moderate | 35 | 47 | 46 | 55 |
| Week 4: Good | 7 | 15 | 16 | 23 |
| Week 8: None | 54 | 36 | 24 | 12 |
| Week 8: Moderate | 36 | 39 | 54 | 54 |
| Week 8: Good | 10 | 25 | 21 | 35 |
| Week 12: None | 49 | 31 | 20 | 14 |
| Week 12: Moderate | 38 | 46 | 53 | 41 |
| Week 12: Good | 14 | 24 | 27 | 45 |
| Week 24: None | — | 28 | 9 | 10 |
| Week 24: Moderate | — | 36 | 41 | 43 |
| Week 24: Good | — | 36 | 50 | 46 |
A participant's disease activity status can be defined as being in remission when scores on the TJC28, SJC28, CRP (actual value in mg/dL) and Patient Global Assessment of Disease Activity (cm) are all ≤ 1. Non-responder imputation was used. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.
| percentage of participants | Placebo | GLPG0634 50 mg QD | GLPG0634 100 mg QD | GLPG0634 200 mg QD |
|---|---|---|---|---|
| Week 4 | 0 | 1.4 | 0 | 1.4 |
| Week 8 | 0 | 0 | 0 | 7.2 |
| Week 12 | 1.4 | 1.4 | 4.3 | 4.3 |
| Week 24 | — | 8.3 | 8.6 | 8.7 |
The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, Patient Global Assessment of Disease Activity (in cm), Physician's Global Assessment of Disease Activity (in cm), and CRP (mg/dL). The SDAI was categorized as follows: • High disease activity: SDAI \> 26 • Moderate disease activity: 11 to 26 • Low disease activity: 3.3 to 11 • Remission: ≤ 3.3. LOCF algorithm was used. The SDAI total score ranges from 0 to approximately 86. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.
| units on a scale | Placebo | GLPG0634 50 mg QD | GLPG0634 100 mg QD | GLPG0634 200 mg QD |
|---|---|---|---|---|
| Baseline | 45.73 ± 1.4789 | 43.77 ± 1.5609 | 46.608 ± 1.6538 | 44.139 ± 1.5079 |
| Change at Week 1 | -7.45 ± 1.5528 | 9.596 ± 1.2567 | -10.886 ± 1.6511 | -14.349 ± 1.4346 |
| Change at Week 2 | -10.022 ± 1.371 | -12.194 ± 1.5982 | -13.172 ± 1.6209 | -18.27 ± 1.6934 |
| Change at Week 4 | -10.927 ± 1.7771 | -17.57 ± 1.7653 | -18.862 ± 1.8073 | -21.288 ± 1.6619 |
| Change at Week 8 | -12.452 ± 1.7748 | -20.144 ± 1.9425 | -23.119 ± 1.8041 | -25.556 ± 1.6949 |
| Change at Week 12 | -12.574 ± 1.984 | -21.413 ± 1.7953 | -25.269 ± 1.9856 | -26.499 ± 1.7534 |
| Change at Week 24 | — | -23.16 ± 1.9364 | -30.983 ± 1.7732 | -29.564 ± 1.8583 |
The CDAI is the SDAI modified to exclude CRP and is the sum of the 4 outcome parameters: TJC28, SJC28, Patient Global Assessment of Disease Activity (in cm), and Physician's Global Assessment of Disease Activity (in cm). The CDAI was be categorized as follows: • High disease activity: \> 22 • Moderate disease activity: 10 to 22 • Mild disease activity: 2.8 to 10 • Remission: ≤ 2.8. LOCF algorithm was used. The CDAI total score ranges from 0 to approximately 76. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.
| units on a scale | Placebo | GLPG0634 50 mg QD | GLPG0634 100 mg QD | GLPG0634 200 mg QD |
|---|---|---|---|---|
| Baseline | 42.168 ± 1.3272 | 41.438 ± 1.4777 | 44.052 ± 1.5383 | 41.869 ± 1.423 |
| Change at Week 1 | -6.867 ± 1.4538 | -9.226 ± 1.1545 | -9.853 ± 1.5591 | -13.148 ± 1.4085 |
| Change at Week 2 | -9.861 ± 1.1909 | -11.803 ± 1.5275 | -12.306 ± 1.5618 | -16.999 ± 1.702 |
| Change at Week 4 | -10.743 ± 1.7184 | -16.701 ± 1.7003 | -17.654 ± 1.6987 | -20.044 ± 1.6396 |
| Change at Week 8 | -12.071 ± 1.6982 | -19.087 ± 1.8583 | -21.703 ± 1.7491 | -24.228 ± 1.6479 |
| Change at Week 12 | 11.696 ± 1.8752 | -21.019 ± 1.7168 | -24.044 ± 1.9665 | -25.071 ± 1.742 |
| Change at Week 24 | — | -22.278 ± 1.8637 | -29.502 ± 1.6928 | -28.102 ± 1.818 |
FACIT-Fatigue scale is a 13-item questionnaire, each scored on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated that are scored reversely), the greater the fatigue. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score), with a higher score indicating a better quality of life. LOCF algorithm was used. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.
| units on a scale | Placebo | GLPG0634 50 mg QD | GLPG0634 100 mg QD | GLPG0634 200 mg QD |
|---|---|---|---|---|
| Baseline | 25.1 ± 1.12 | 25.1 ± 1.28 | 24.8 ± 1.13 | 24.8 ± 1.16 |
| Change at Week 4 | 1.4 ± 1.14 | 7.2 ± 1.3 | 7.2 ± 1.26 | 8.5 ± 1.3 |
| Change at Week 12 | 3.9 ± 1.23 | 9.5 ± 1.43 | 10.2 ± 1.21 | 11.2 ± 1.44 |
| Change at Week 24 | — | 10 ± 1.43 | 11.3 ± 1.2 | 13.7 ± 1.38 |
The SF-36 is a 36-item questionnaire measuring 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health). Each domain score ranges from 0 (worst) to 100 (best), with higher scores reflecting better health-related functional status. Two summary scale scores were computed based on weighted combinations of the 8 domain scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). LOCF algorithm was used. All placebo participants switched to GLPG0634 treatment at Week 12 and were not included in the analysis of Week 24.
| units on a scale | Placebo | GLPG0634 50 mg QD | GLPG0634 100 mg QD | GLPG0634 200 mg QD |
|---|---|---|---|---|
| PCS at Baseline | 31.1 ± 0.6988 | 31.05 ± 0.816 | 30.946 ± 0.7631 | 31.804 ± 0.8965 |
| PCS Change at Week 4 | 2.1 ± 0.72 | 5.7 ± 1.04 | 5.1 ± 0.92 | 6.8 ± 0.92 |
| PCS Change at Week 12 | 3 ± 0.89 | 7.1 ± 1.11 | 7.8 ± 1.04 | 8.6 ± 1.09 |
| PCS Change at Week 24 | — | 6.9 ± 1.16 | 10 ± 1.17 | 9.7 ± 1.09 |
| MCS at Baseline | 40.525 ± 1.3053 | 42.793 ± 1.3247 | 41.185 ± 1.2347 | 42.613 ± 1.1674 |
| MCS at Week 4 | 2.1 ± 1.1 | 3.6 ± 1.09 | 5.3 ± 1.04 | 3.9 ± 1.16 |
| MCS at Week 12 | 2.7 ± 1.04 | 4.9 ± 1.18 | 6.9 ± 1.04 | 6.8 ± 1.33 |
| MCS at Week 24 | — | 5.1 ± 1.27 | 7.7 ± 1.16 | 8.5 ± 1.12 |
Collected over Baseline through end of study drug treatment (average exposure: 161.0 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/72 (0%) | 1/72 (1.4%) | 9/72 (12.5%) |
| GLPG0634 50 mg QD | 0/72 (0%) | 2/72 (2.8%) | 14/72 (19.4%) |
| GLPG0634 100 mg QD | 0/85 (0%) | 3/85 (3.5%) | 21/85 (24.7%) |
| GLPG0634 200 mg QD | 0/69 (0%) | 3/69 (4.3%) | 16/69 (23.2%) |
| Event | Placebo | GLPG0634 50 mg QD | GLPG0634 100 mg QD | GLPG0634 200 mg QD |
|---|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 0/72 | 0/72 | 0/85 | 1/69 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/72 | 0/72 | 0/85 | 1/69 |
| PneumoniaInfections and infestations | 0/72 | 0/72 | 0/85 | 1/69 |
| Humerus fractureInjury, poisoning and procedural complications | 0/72 | 1/72 | 0/85 | 0/69 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 1/72 | 0/72 | 0/85 | 0/69 |
| GastroenteritisInfections and infestations | 0/72 | 1/72 | 0/85 | 0/69 |
| VertigoEar and labyrinth disorders | 0/72 | 0/72 | 1/85 | 0/69 |
| CellulitisInfections and infestations | 0/72 | 0/72 | 1/85 | 0/69 |
| Pyelonephritis chronicInfections and infestations | 0/72 | 0/72 | 1/85 | 0/69 |
| Event | Placebo | GLPG0634 50 mg QD | GLPG0634 100 mg QD | GLPG0634 200 mg QD |
|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 1/72 | 3/72 | 7/85 | 4/69 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 3/72 | 4/72 | 5/85 | 1/69 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 1/72 | 2/72 | 5/85 | 1/69 |
| AnaemiaBlood and lymphatic system disorders | 0/72 | 1/72 | 0/85 | 4/69 |
| Upper respiratory tract infectionInfections and infestations | 2/72 | 2/72 | 4/85 | 4/69 |
| HypertensionVascular disorders | 4/72 | 3/72 | 1/85 | 2/69 |
| HeadacheNervous system disorders | 1/72 | 4/72 | 1/85 | 3/69 |
Safety population included all participants who were randomized and received at least one dose of study medication.
| Age, Continuous(years) | Placebo | GLPG0634 50 mg QD | GLPG0634 100 mg QD | GLPG0634 200 mg QD | Total |
|---|---|---|---|---|---|
| Mean | 51.5 (20 to 77) | 52.1 (18 to 79) | 52.8 (22 to 78) | 51.8 (25 to 79) | 52.1 (18 to 79) |
| Sex: Female, Male(Participants) | Placebo | GLPG0634 50 mg QD | GLPG0634 100 mg QD | GLPG0634 200 mg QD | Total |
|---|---|---|---|---|---|
| Female | 56 | 62 | 53 | 60 | 231 |
| Male | 16 | 10 | 17 | 9 | 52 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | GLPG0634 50 mg QD | GLPG0634 100 mg QD | GLPG0634 200 mg QD | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 25 | 23 | 25 | 25 | 98 |
| Not Hispanic or Latino | 47 | 49 | 45 | 44 | 185 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | GLPG0634 50 mg QD | GLPG0634 100 mg QD | GLPG0634 200 mg QD | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 1 |
| Black or African American | 1 | 1 | 1 | 0 | 3 |
| White | 53 | 53 | 53 | 54 | 213 |
| More than one race | 17 | 17 | 16 | 15 | 65 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Rheumatoid Arthritis (RA) duration(years) | Placebo | GLPG0634 50 mg QD | GLPG0634 100 mg QD | GLPG0634 200 mg QD | Total |
|---|---|---|---|---|---|
| Mean | 9.46 (0.7 to 28.9) | 8.63 (0.5 to 23.4) | 8.57 (0.5 to 33.7) | 8.68 (0.5 to 49.6) | 8.84 (0.5 to 49.6) |
| C-reactive protein (CRP) at Baseline(milligram per liter (mg/L)) | Placebo | GLPG0634 50 mg QD | GLPG0634 100 mg QD | GLPG0634 200 mg QD | Total |
|---|---|---|---|---|---|
| Mean | 35.26 (1 to 175) | 24.67 (1 to 162.9) | 25.55 (1.6 to 244.1) | 23.16 (1 to 91.3) | 27.21 (1.0 to 244.1) |
| Corrected tender joint count based on 68 joints (TJC68) at Baseline(joint count) | Placebo | GLPG0634 50 mg QD | GLPG0634 100 mg QD | GLPG0634 200 mg QD | Total |
|---|---|---|---|---|---|
| Mean | 25.226 (8 to 63) | 25.58 (9 to 64) | 27.195 (8 to 65) | 26.242 (8 to 65.94) | 26.051 (8 to 65.94) |
| Corrected swollen joint count based on 66 joints (SJC66) at Baseline(joint count) | Placebo | GLPG0634 50 mg QD | GLPG0634 100 mg QD | GLPG0634 200 mg QD | Total |
|---|---|---|---|---|---|
| Mean | 15.98 (7 to 38) | 16.969 (7 to 48) | 18.653 (6 to 56) | 15.74 (6 to 46) | 16.834 (6 to 56) |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2013 to primary completion in Mar 2015, 16 months.
Results were first posted in Nov 2020, 5 years 8 months after primary completion. A results delay was requested in Apr 2016.
Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 16 months is close to that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GLPG0634